Form 4: Immunome Director Receives Stock Option Grant

Director Carol Schafer was granted 9,897 stock options in Immunome, Inc. as part of a standard equity compensation plan.

Summary

• Director Carol Schafer received a grant of 9,897 stock options for Immunome, Inc. (IMNM) common stock.
• The options have an exercise price of $18.16 per share.
• The grant date for these options is June 10, 2026.
• The options are scheduled to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of Immunome common stock.

Future Outlook

The options vest in four equal quarterly installments starting June 10, 2026, through the one-year anniversary, contingent upon the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of quarterly vesting over one year for director options is consistent with standard industry practices for small-to-mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options in four equal quarterly installments beginning June 10, 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Stock Options, Director Compensation, Insider Transaction